Akoya Biosciences (AKYA)
(Delayed Data from NSDQ)
$2.88 USD
-0.03 (-1.03%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.90 +0.02 (0.69%) 7:42 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Akoya Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -63.32 | -70.64 | -42.94 | -16.71 | -14.75 |
Depreciation/Amortization & Depletion | 8.89 | 7.15 | 4.79 | 3.82 | 3.06 |
Net Change from Assets/Liabilities | -12.06 | 2.16 | -4.56 | 2.39 | -1.38 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.59 | 7.83 | 6.64 | 3.65 | -0.70 |
Net Cash From Operating Activities | -50.90 | -53.50 | -36.07 | -6.84 | -13.78 |
Property & Equipment | -3.65 | -7.31 | -5.09 | -3.30 | -2.87 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 7.00 | -6.77 | 0.00 | 10.17 | -10.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -0.15 | -0.02 |
Net Cash from Investing Activities | 3.35 | -14.08 | -5.09 | 6.73 | -12.89 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.35 | 0.45 | 138.95 | 0.12 | 24.83 |
Issuance (Repayment) of Debt | 10.57 | 30.63 | -0.32 | 9.79 | 4.96 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 45.92 | -2.35 | -1.59 | -4.42 | -1.23 |
Net Cash from Financing Activities | 56.84 | 28.73 | 137.04 | 5.49 | 28.56 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 9.29 | -38.85 | 95.87 | 5.37 | 1.89 |
Cash at Beginning of Period | 74.53 | 113.38 | 17.51 | 12.14 | 10.24 |
Cash at End of Period | 83.82 | 74.53 | 113.38 | 17.51 | 12.14 |
Diluted Net EPS | -1.43 | -1.87 | -1.65 | -9.18 | NA |
Fiscal Year End for Akoya Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -36.63 | -23.48 | -63.32 | -52.52 | -39.61 |
Depreciation/Amortization & Depletion | 3.98 | 2.05 | 8.89 | 6.78 | 4.21 |
Net Change from Assets/Liabilities | -10.86 | -7.49 | -12.06 | -11.61 | -2.27 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.65 | 8.10 | 15.59 | 12.03 | 6.11 |
Net Cash From Operating Activities | -31.87 | -20.82 | -50.90 | -45.32 | -31.56 |
Property & Equipment | -0.98 | -0.81 | -3.65 | -3.06 | -2.23 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -38.78 | -48.01 | 7.00 | 7.00 | 7.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -39.76 | -48.82 | 3.35 | 3.94 | 4.77 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.06 | 0.04 | 0.35 | 0.31 | 0.20 |
Issuance (Repayment) of Debt | -0.35 | -0.18 | 10.57 | -0.50 | -0.32 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.27 | -0.30 | 45.92 | 45.95 | 46.03 |
Net Cash from Financing Activities | -2.57 | -0.44 | 56.84 | 45.77 | 45.91 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -74.20 | -70.09 | 9.29 | 4.39 | 19.12 |
Cash at Beginning of Period | 83.82 | 83.82 | 74.53 | 74.53 | 74.53 |
Cash at End of Period | 9.63 | 13.74 | 83.82 | 78.93 | 93.65 |
Diluted Net EPS | -0.27 | -0.48 | -0.17 | -0.26 | -0.51 |